1
|
Torrance F, Purshouse K, Hall P, Mackean M, Phillips I. MA10.10 Lung Cancer Admission Rates During the COVID-19 Pandemic to a Tertiary Cancer Centre in South East Scotland. J Thorac Oncol 2021. [PMCID: PMC7976859 DOI: 10.1016/j.jtho.2021.01.246] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
2
|
Best J, Starkey T, Chatterjee A, Fackrell D, Pettit L, Srihari N, Tween H, Olsson-Brown A, Cheng V, Hughes DJ, Lee AJX, Purshouse K, Arnold R, Uk Coronavirus Cancer Monitoring Project Team, Sivakumar S, Cazier JB, Lee LYW. Coronavirus Disease 2019: the Pivotal Role of UK Clinical Oncology and the UK Coronavirus Cancer Monitoring Project. Clin Oncol (R Coll Radiol) 2021; 33:e50-e53. [PMID: 32593552 PMCID: PMC7274595 DOI: 10.1016/j.clon.2020.05.021] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2020] [Revised: 05/20/2020] [Accepted: 05/28/2020] [Indexed: 01/08/2023]
Affiliation(s)
- J Best
- Shrewsbury and Telford Hospital NHS Trust, Royal Shrewsbury Hospital, Shrewsbury, UK
| | - T Starkey
- Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK
| | - A Chatterjee
- Shrewsbury and Telford Hospital NHS Trust, Royal Shrewsbury Hospital, Shrewsbury, UK
| | - D Fackrell
- Queen Elizabeth Hospital, University Hospitals Birmingham, Birmingham, UK
| | - L Pettit
- Shrewsbury and Telford Hospital NHS Trust, Royal Shrewsbury Hospital, Shrewsbury, UK
| | - N Srihari
- Shrewsbury and Telford Hospital NHS Trust, Royal Shrewsbury Hospital, Shrewsbury, UK
| | - H Tween
- University Hospitals Coventry and Warwickshire, Coventry, UK
| | | | - V Cheng
- Leeds Cancer Centre, Bexley Wing, St James's University Hospital, Leeds, UK
| | - D J Hughes
- Department of Cancer Imaging, Division of Cancer Studies, Guy's Campus, King's College London, London, UK
| | - A J X Lee
- University College London, UCL Cancer Institute, London, UK
| | - K Purshouse
- Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
| | - R Arnold
- Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK
| | | | - S Sivakumar
- Department of Oncology, University of Oxford, Oxford, UK
| | - J-B Cazier
- Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK; Centre for Computational Biology, University of Birmingham, Birmingham, UK
| | - L Y W Lee
- Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.
| |
Collapse
|
3
|
Olsson-Brown A, Hughes D, Purshouse K, Lee L, Cheng V, Lee A, Protheroe E, Smith A, Curley H, Arnold R, Cazier JB, D'Costa J, Palles C, Campton N, Varnai C, Sivakumar S, Kerr R, Middleton G. 1703P UK Coronavirus Cancer Monitoring Project (UKCCMP): A national reporting network for real time data of the COVID-19 pandemic. Ann Oncol 2020. [PMCID: PMC7506390 DOI: 10.1016/j.annonc.2020.08.1767] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
4
|
Purshouse K, Woodcock V, Butcher C, Haddon C, Verrall G, Elhussein L, Salio M, Middleton M, Cerundolo V, Kwok J, Blagden S, Protheroe A, Crew J. A phase I study to assess the safety and tolerability of intravesical pembrolizumab in recurrent non-muscle invasive bladder cancer (NMIBC). ACTA ACUST UNITED AC 2019. [DOI: 10.1016/s1569-9056(19)30564-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
5
|
da Motta LL, Ledaki I, Purshouse K, Haider S, De Bastiani MA, Baban D, Morotti M, Steers G, Wigfield S, Bridges E, Li JL, Knapp S, Ebner D, Klamt F, Harris AL, McIntyre A. The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancer. Oncogene 2017; 36:122-132. [PMID: 27292261 PMCID: PMC5061082 DOI: 10.1038/onc.2016.184] [Citation(s) in RCA: 103] [Impact Index Per Article: 14.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2015] [Revised: 03/22/2016] [Accepted: 04/15/2016] [Indexed: 12/16/2022]
Abstract
The availability of bromodomain and extra-terminal inhibitors (BETi) has enabled translational epigenetic studies in cancer. BET proteins regulate transcription by selectively recognizing acetylated lysine residues on chromatin. BETi compete with this process leading to both downregulation and upregulation of gene expression. Hypoxia enables progression of triple negative breast cancer (TNBC), the most aggressive form of breast cancer, partly by driving metabolic adaptation, angiogenesis and metastasis through upregulation of hypoxia-regulated genes (for example, carbonic anhydrase 9 (CA9) and vascular endothelial growth factor A (VEGF-A). Responses to hypoxia can be mediated epigenetically, thus we investigated whether BETi JQ1 could impair the TNBC response induced by hypoxia and exert anti-tumour effects. JQ1 significantly modulated 44% of hypoxia-induced genes, of which two-thirds were downregulated including CA9 and VEGF-A. JQ1 prevented HIF binding to the hypoxia response element in CA9 promoter, but did not alter HIF expression or activity, suggesting some HIF targets are BET-dependent. JQ1 reduced TNBC growth in vitro and in vivo and inhibited xenograft vascularization. These findings identify that BETi dually targets angiogenesis and the hypoxic response, an effective combination at reducing tumour growth in preclinical studies.
Collapse
Affiliation(s)
- L L da Motta
- Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
- Department of Biochemistry/UFRGS, Porto Alegre, Brazil
- CAPES Foundation, Ministry of Education of Brazil, Brasilia, Brazil
| | - I Ledaki
- Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
| | - K Purshouse
- Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
| | - S Haider
- Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
| | | | - D Baban
- High Throughput Genomics, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK
| | - M Morotti
- Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
| | - G Steers
- Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
| | - S Wigfield
- Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
| | - E Bridges
- Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
| | - J-L Li
- Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
- Institute of Translational and Stratified Medicine, Plymouth University, Peninsula Schools of Medicine and Dentistry, Plymouth, UK
| | - S Knapp
- Nuffield Department of Clinical Medicine, Structural Genomics Consortium, University of Oxford, Oxford, UK
- Goethe University Frankfurt, Institute for Pharmaceutical Chemistry and Buchmann Institute for Life Sciences, Campus Riedberg, Frankfurt, Germany
| | - D Ebner
- Nuffield Department of Medicine, Target Discovery Institute (TDI), University of Oxford, Oxford, UK
| | - F Klamt
- Department of Biochemistry/UFRGS, Porto Alegre, Brazil
| | - A L Harris
- Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
| | - A McIntyre
- Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
- Cancer Biology, Division of Cancer and Stem Cells, The University of Nottingham, Nottingham, UK
| |
Collapse
|
6
|
Sinha R, Lecamwasam K, Purshouse K, Reed J, Middleton MR, Fearfield L. Toxic epidermal necrolysis in a patient receiving vemurafenib for treatment of metastatic malignant melanoma. Br J Dermatol 2015; 170:997-9. [PMID: 24359127 DOI: 10.1111/bjd.12796] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- R Sinha
- Department of Dermatology, Chelsea and Westminster Hospital, 369 Fulham Road, London, SW10 9NH, U.K
| | | | | | | | | | | |
Collapse
|
7
|
Sturge J, Caley MP, Purshouse K, Fonseca AV, Rodriguez-Teja M, Kogianni G, Waxman J, Palmieri C. Abstract P2-02-03: The Collagen Receptor Endo180: A Metastatic Plasma Marker In Breast Cancer Modulated By Bisphosphonate Treatment. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p2-02-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose: To establish whether the collagen remodelling receptor, Endo180, should be given consideration as a useful plasma marker in metastatic breast cancer.
Patients and Methods: Analysis of MCF-7 and MDA-MB-231 cell conditioned medium validated the anti-human (39.10) monoclonal antibody as suitable for the detection of soluble Endo180 in plasma. Eighty-seven breast cancer patients with early primary, locally advanced and metastatic disease were included in the study. Correlations between Endo180, CA 15–3 antigen (MUC1; mucin 1) and bisphosphonate treatment were investigated.
Results: Endo180 was elevated in metastatic compared to early breast cancer (P <.0001) and was able to differentiate locoregional disease and visceral and/or osseous metastasis (P = .0005). In combination CA 15–3 antigen (cut-off: 28 U/mL) and Endo180 (relative plasma level cut-off range: 0.95–1.65) had sensitivity of 94–97% and specificity of 52–68%. Endo180 levels were significantly higher in patients who were treatment naive (2.17 ± 0.82, N = 13) compared to those previously (1.82 ± 0.33, N = 5) or currently (1.37 ± 0.74, N = 24) receiving bisphosphonates (P = .011). In the bisphosphonate naive setting (N = 57) the combination of Endo180 (relative plasma level cut-off range: 0.95–1.65) and CA 15–3 antigen (cut-off: 28 U/mL) had a sensitivity of 87–92% and specificity of 72–79%.
Conclusion: Endo180 is a plasma marker with high sensitivity in metastatic breast cancer that can be modulated by bisphosphonate treatment.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P2-02-03.
Collapse
Affiliation(s)
- J Sturge
- Imperial College London, United Kingdom; The University of Hull, Hull, United Kingdom
| | - MP Caley
- Imperial College London, United Kingdom; The University of Hull, Hull, United Kingdom
| | - K Purshouse
- Imperial College London, United Kingdom; The University of Hull, Hull, United Kingdom
| | - A-V Fonseca
- Imperial College London, United Kingdom; The University of Hull, Hull, United Kingdom
| | - M Rodriguez-Teja
- Imperial College London, United Kingdom; The University of Hull, Hull, United Kingdom
| | - G Kogianni
- Imperial College London, United Kingdom; The University of Hull, Hull, United Kingdom
| | - J Waxman
- Imperial College London, United Kingdom; The University of Hull, Hull, United Kingdom
| | - C Palmieri
- Imperial College London, United Kingdom; The University of Hull, Hull, United Kingdom
| |
Collapse
|
8
|
Andrade J, Purshouse K, Mukaetova-Ladinska E. Can healthy lifestyle modify risk factors for dementia? findings from a pilot population-based survey. Eur Psychiatry 2011. [DOI: 10.1016/s0924-9338(11)72189-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
IntroductionAspects of lifestyle are a key component to successful ageing and reducing the risk of cognitive impairment. Many developing countries, including India, currently have a much lower rate of dementia in people of the same age in the UK (Alzheimer’s Disease International 2008), in contrast to the higher prevalence rates of cardiovascular risk factors (reviewed in Misra and Kurana, 2009).ObjectivesCompare lifestyle choices in a developed and a developing country, that show contrasting dementia prevalence rates.AimsIdentify protective factors that may reduce dementia prevalence.MethodsA total of 251 participants at public meetings (123 in Newcastle and 128 in Chennai) on ageing completed a questionnaire voluntarily regarding their lifestyle, health status, 4-item GDS, and their subjective perception of their mental and physical health. The two groups had similar sociodemographic characteristics.ResultsDiabetes was three times more prevalent in the Chennai group (p = 0.001) but a significantly higher proportion of the Chennai population reported receiving treatment for diabetes (p = 0.012). Vegeterian diet was more frequent in the Chennai cohort (p = 0.000), as well as curry consumption (p = 0.000). The Newcastle group consumed more alcohol (p = 0.000) and practiced exercise less often (p = 0.005). Not surprinsingly, 95% of the Indian is religious, in contrast to 59.7% of the English (p = 0.000).ConclusionsType of diet, curry and alcohol consumption, and religious or spiritual beliefs, were the most significantly different, and may therefore confer protective advantages for dementia. Other explanations could be a higher proportion of uncontrolled diabetes and inactive people in the Newcastle sample.
Collapse
|